Lappe Mark

CEO Lappe Mark purchased 40,000 shares at blended $15.73 on Sept 12–16; stock now $17.43, +39.9% in 30 days.

Mark Lappe, CEO of Inhibrx Biosciences, executed 2 separate purchases totaling 40,000 shares (40.0K shares) for $629,116.96 ($629.1K) between September 12–16, at prices of $15.05 and $17.13. His stake increased 6.0% to 705,548 shares. The timing is notable: the stock traded at a 52-week low near $11.04 and has since recovered +39.9% over 30 days and +19.6% over 90 days to the current $17.43 price, indicating a near-term reversal from depressed levels. Prior purchases at INBX on September 3, 6, 9, and 10 signal sustained accumulation over a narrow window, though 30-day and 90-day returns for those trades remain unmeasurable. The fundamentals present a stark anomaly: quarterly revenue of $100,000.00 against net income of $1,858,011,000.00 ($1.9B) reflects either an accounting event (e.g., non-cash gain or restructuring) or a data quality issue requiring clarification. An investor should establish whether the large net income is an operational reality or a one-time item, as it materially affects the valuation context for the CEO's accumulation pattern.

CEO Mark Lappe purchased 44,000 shares at avg $15.25 across 3 transactions in early Sept; blended with cluster of 2 other insider buys in past 14 days.

Mark Lappe, Chief Executive Officer, executed 3 separate purchases totaling 44,000 shares for $671,150.00 between September 6-10, 2024, at prices ranging from $15.19 to $15.29—near the current price of $15.18 and well below the 52-week high of $39.56. His holdings increased 7.1% to 665,548 shares post-transaction. Notably, this buying activity occurred as part of a broader cluster pattern: 2 other insiders also purchased shares within the past 14 days, and Lappe himself executed 5 additional buys at INBX during late August and early September (most recent on 2024-09-03), suggesting sustained accumulation by company leadership during a period when the stock is down 61.6% from its 52-week high. The revenue figure ($100,000.00 latest quarter) appears anomalously low relative to the $1.9B net income and $219.7M market cap, warranting deeper scrutiny into the financial health and reporting accuracy of the company fundamentals.

CEO Lappe Mark buys 40,000 shares across 4 transactions totaling $596,762.80; 3 other insiders also bought within 14 days.

Mark Lappe, Chief Executive Officer of Inhibrx Biosciences, executed 4 separate purchases totaling 40,000 shares for $596,762.80 between 2024-08-29 and 2024-09-03, raising his holdings from 125,000 to 165,000 shares (+32.0% vs pre-transaction holdings). The buys occurred at prices ranging from $14.02 to $16.31, with a blended average of $14.92, while the current price stands at $15.95—above the average transaction price. The company's latest revenue was $100,000.00 and net income was $1,858,011,000.00, though the revenue figure appears materially inconsistent with net income scale and warrants verification. A cluster pattern is present: 3 other insiders also bought within the past 14 days, concentrating insider accumulation activity during a period when the stock is -59.7% from its 52-week high of $39.56.

CEO Lappe purchases 40,000 shares (40.0K) for $518,282.20 across 2 transactions; holdings surge 269.1% to 54.9K shares

Mark Lappe, Chief Executive Officer of Inhibrx Biosciences, executed 2 separate purchases totaling 40,000 shares for $518,282.20 at a blended average price of $12.96 over August 20–21. This transaction represents a 269.1% increase in his holdings, from 14,865 shares to 54.9K shares post-transaction. The timing coincides with a period of significant stock weakness: the stock is trading at -67.2% from its 52-week high of $39.56 and has declined -62.0% over the past 90 days and -8.8% over the past 30 days. The company's financial profile shows highly unusual metrics: minimal quarterly revenue of $100,000.00 against net income of $1.9B, suggesting potential data anomalies or structural complexities that warrant scrutiny. An investor should investigate the source and sustainability of these earnings figures and monitor whether the CEO's substantial equity acquisition reflects conviction in the company's trajectory or a response to near-term valuation dislocations.